KRAS and colorectal cancer: In colorectal cancer, the KRAS glycine-to-cysteine mutation at codon 12 (KRAS G12C) occurs in up to 4% of patients and is associated with poorer overall survival (OS) in the first and second line when treated with chemotherapy.